Abstract
Introduction
Disturbed sleep is a common and distressing problem affecting more than one-third of cancer patients both during and after completion of active treatment 1, 2 . Despite its prevalence, insomnia is frequently rationalised as a transient side-effect of diagnosis-related stress or cancer treatment [3] [4] [5] .
Incidence data show however, that more than one quarter of cancer patients with sleep disturbance experience chronic insomnia, which fails to remit even when active cancer treatment has ceased 4 .
Sleep disturbance is often associated with other symptoms like fatigue, anxiety and depression [5] [6] [7] [8] [9] . Portenoy et. al. demonstrated that this cluster was highly prevalent (40-80%) across different tumour types 10 , and recent work by Liu et al. found that the presence of pre-treatment symptom clusters in breast cancer patients was associated with poorer sleep, increased fatigue and lower mood during active treatment 11 . Therefore each symptom seems to maintain and exacerbate the others, resulting in further impairment to quality of life.
Such inter-relationships have also been studied in the general population. For example, psychiatric epidemiology indicates that insomnia is an independent risk factor for the development of first episode depressive disorder in adults of all ages 12 . Similarly, people with cancer and insomnia report decreased functioning, more pain and higher levels of fatigue than those sleeping well 13, 14 . Sharma et al. 15 found that nearly a third of patients attending a Regional Cancer Centre reported sleep problems of clinical significance which were strongly associated with symptoms of emotional distress. The nature of these associations requires further study.
Implementing a programme of Cognitive Behaviour Therapy for insomnia (CBT-I) in cancer patients yields generalised improvements in other symptoms including fatigue, quality of life and daytime functioning 16,17 , suggesting that these symptoms share common pathways 8, 18, 19 .
The aims of this paper are: (i) to report on the rates of and associations between co-morbid clinical symptoms of insomnia, fatigue, anxiety and depression in a sample of cancer patients, (ii) to investigate potential generalised effects on these symptoms following CBT-I and (iii) to assess the clinical significance of any such improvement.
Methods

Experimental Design
This is a secondary analysis of data from 113 patients, derived from a randomised controlled clinical effectiveness trial of CBT-I versus treatment as usual (TAU) for insomnia in cancer patients 16 . CBT comprised five, small group sessions across consecutive weeks, following a manualised protocol.
TAU represented normal clinical practice; the appropriate control for a clinical effectiveness study. The trial conformed to a pragmatic, two-centre design comparing CBT-I with TAU. Major assessments were at baseline, posttreatment and follow-up 6 months later (6-month assessment is not reported due to missing data). Suitable participants were randomly allocated to either CBT-I or TAU by means of a centralised computer-based registration/randomisation service available within the Cancer Research UK Clinical Trials Unit, Glasgow. The study was stratified for centre, existing treatment for insomnia and tumour type using the minimisation method. A 2:1 treatment allocation, in favour of the intervention, was selected because this would make more efficient use of available CBT-I sessions and would minimise the time a patient had to wait before being able to start a CBT-I course, thereby reducing patient dropout.
Due to the nature of the intervention, it was not possible to blind participants or therapists to allocation.
No adverse events were reported with either CBT-I or TAU. Participants were excluded if they had acute illness, estimated prognosis <6 months, another sleep disorder, confusional problems or untreated and unstable psychiatric disorder (screening procedures did not identify anyone with untreated/unstable psychiatric disorder so therefore, no-one was excluded on the basis of their psychiatric history).
Potential participants were notified of the study by posters/leaflets in clinic waiting areas, by mailing information to those attending upcoming clinics or directly by staff upon attendance at clinics. All participants provided written informed consent and their medical consultant agreed to their participation.
The protocol was approved by local NHS research ethics committees.
Insert Table I Measures
We conducted a secondary analysis of sleep-onset latency (SOL) and wake time after sleep onset (WASO), anxiety and depression and fatigue (severity and interference), using a ten day Sleep Diary 24 , the Hospital Anxiety and Depression Scale (HADS) 25 and the Fatigue Symptom Inventory (FSI) 26 .
Sleep diaries are the staple tool of insomnia assessment practice and offer a valid, relative index of sleep disturbance when used as repeated measures. 27 Participants were trained to complete sleep diaries using established criteria for accurate completion 28 . The HADS has been validated for use in cancer patients to screen for anxiety and depressive symptoms 29, 30 .
It is a particularly useful measure for assessing mood in sleep research, as unlike many other anxiety/depression questionnaires, the HADS does not contain a sleep-specific item. The FSI is also recommended for use with cancer patients, as a brief measure with good validity and internal consistency 26, 31 . Median values for these scales (and subscales) are presented in Table I .
In order to understand poly-symptomatic associations between insomnia and clinical level symptoms of fatigue, anxiety and depression, baseline data were re-analysed to isolate only those participants scoring beyond recognised clinical cut-offs for insomnia and at least one other domain. Therefore, 'anxiety' refers to HADS anxiety scores of ≥ 11 29, 30 , 'depression' refers to HADS depression scores of ≥ 11 29, 30 and 'fatigue' refers to fatigue severity and/or interference scores of ≥ 3 on the FSI 31, 32 . Applying these criteria 1 to the data meant that 37 participants, who were included in the analyses for the original trial, were excluded from this secondary analysis.
This means that the proportions presented in the results section relates only to patients who presented with comorbidity at baseline.
Statistical methods
The RCT was designed to have 80% power to detect a standardized difference of 0.5 between the treatments in the primary sleep outcome measures at post-treatment. A significance level of 0.0125 was chosen to 1 In order to enhance the validity of our results, we opted to use a cut-off of 11 on the HADS.
We acknowledge that this potentially reduces the possibility of identifying clinical cases of depression and anxiety and therefore, higher rates of comorbidity. However, we feel that the integrity of our results is enhanced by applying more rigorous criteria to the diagnosis of clinical mood symptoms.
adjust for multiple comparisons. These criteria implied recruiting 204 participants. In practice, slow recruitment meant that a total of 150 patients were randomly assigned, giving 80% power to detect a slightly larger standardized difference of 0.59.
Results
Descriptive analysis of baseline data across the entire sample (n=113)
showed that alongside clinical levels of insomnia, 76 participants (67%) also reported levels of fatigue that reached or exceeded clinical cut-offs. This was the most common symptom profile. The next most common presentation was 'insomnia + fatigue + anxiety', reported by 20 individuals (18% of the total sample). 6 participants (5%) scored above clinical cut-offs for all symptoms and 'insomnia + fatigue + depression' also accounted for 5% of the sample.
The least common symptom presentations were 'insomnia + anxiety' (3 participants), 'insomnia + anxiety + depression' (2 participants) and 'insomnia + depression', accounting for 3%, 2% and 0% of the sample respectively. Overall, we can conclude that there is a significant relationship between group allocation (i.e. CBT or TAU) and changes in clinical levels of insomnia and fatigue. No such relationship was found between group allocation and mood variables.
Worsening of symptoms
Whilst calculating change score data from the CBT group, we discovered that in a small number of cases, symptoms seemed to worsen at post treatment (characterised by post treatment data exceeding clinical levels when baseline data had not). Given that this finding was not isolated to the TAU group, we decided to analyse these individuals separately. Given that all participants had baseline insomnia scores that exceeded clinical cut-offs, it was not possible for insomnia to worsen at post treatment (according to our criteria). Also, it is not surprising that insomnia-related symptoms would worsen in the TAU group over time. Therefore, only those people with worsening symptoms of fatigue, anxiety and depression following CBT is examined. Of the 8 people, 4 reported worsening fatigue, 2 reported worsening anxiety and 2 reported worsening anxiety + depression.
Discussion
All participants in our original trial of CBT versus TAU met criteria for clinical insomnia 16 . However less than a quarter of them (n=37) were troubled by sleep problems alone, with the majority (n=113) experiencing other comorbid symptoms like fatigue, anxiety and depression. Further analysis of this symptom cluster revealed that clinical fatigue was the most common comorbid symptom, experienced by the majority of participants at baseline.
Almost a third of participants in this study presented with three or more coexisting symptoms which exceeded clinical cut-offs. These findings are consistent with previous evidence of the high prevalence of symptom clusters in cancer patients [5] [6] [7] [8] [9] .
At baseline, anxiety was more prevalent than depression across both groups, although the number of participants experiencing clinical levels of either symptom was small. Findings from a large prospective study examining symptoms in early breast cancer patients over 5 years, also reported higher levels of clinically significant anxiety than depression (14.4% vs. 3.1%) 29, 30 .
Our data indicates a relatively small association between clinical insomnia and mood disturbance, which is in contrast to numerous studies reporting high rates of co-morbidity between insomnia and depression and insomnia and anxiety in cancer patients 8, 9, 11, 15 . However, the current study applied strict 
